- Home
- / Sagent Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sagent Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$318.3 M
FY, 2015
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|---|---|
| Revenue | 152.4M | 183.6M | 244.8M | 289.0M | 318.3M |
| Revenue growth, % | 18.1% | 10.1% | |||
| Cost of goods sold | 133.6M | 152.5M | 167.2M | 202.8M | 230.6M |
| Gross profit | 18.8M | 31.1M | 77.5M | 86.2M | 87.7M |
| Gross profit margin, % | 12.3% | 16.9% | 31.7% | 29.8% | 27.6% |
| General and administrative expense | 25.1M | 30.1M | 36.2M | 43.2M | 49.9M |
| Operating expense total | 40.4M | 46.6M | 46.1M | 67.1M | 132.3M |
| EBIT | (21.7M) | (15.5M) | 31.4M | 19.0M | (44.5M) |
| EBIT margin, % | -14.2% | -8.4% | 12.8% | 6.6% | -14.0% |
| Investment income | 284.0K | 243.0K | |||
| Interest income | 39.0K | ||||
| Interest expense | 4.2M | 1.6M | 678.0K | 2.8M | |
| Pre tax profit | (26.4M) | (16.8M) | 30.5M | 16.2M | (48.1M) |
| Income tax expense | 895.0K | (23.7M) | (26.2M) | ||
| Net Income | (26.4M) | (16.8M) | 29.6M | 39.9M | (21.9M) |